ABIVAX Société Anonyme (NASDAQ:ABVX) Short Interest Update

ABIVAX Société Anonyme (NASDAQ:ABVX) was the recipient of a large growth in short interest in the month of September. As of September 30th, there was short interest totalling 272,200 shares, a growth of 31.5% from the September 15th total of 207,000 shares. Approximately 0.5% of the company’s stock are short sold. Based on an average daily trading volume, of 91,800 shares, the days-to-cover ratio is presently 3.0 days.

Analyst Upgrades and Downgrades

Separately, Laidlaw started coverage on shares of ABIVAX Société Anonyme in a research report on Monday, July 29th. They set a “buy” rating and a $48.00 price target for the company. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $36.50.

ABIVAX Société Anonyme Trading Up 6.1 %

Shares of ABIVAX Société Anonyme stock opened at $9.52 on Monday. ABIVAX Société Anonyme has a 1 year low of $7.99 and a 1 year high of $17.02. The firm’s 50-day moving average is $11.26 and its 200 day moving average is $12.94.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ABVX. BNP Paribas Financial Markets purchased a new position in ABIVAX Société Anonyme in the 1st quarter worth approximately $81,000. Capstone Investment Advisors LLC lifted its holdings in shares of ABIVAX Société Anonyme by 9.0% during the first quarter. Capstone Investment Advisors LLC now owns 62,966 shares of the company’s stock valued at $900,000 after purchasing an additional 5,199 shares in the last quarter. Kennedy Capital Management LLC boosted its position in shares of ABIVAX Société Anonyme by 35.3% during the first quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock valued at $1,718,000 after buying an additional 31,331 shares during the last quarter. Finally, Janus Henderson Group PLC increased its holdings in ABIVAX Société Anonyme by 18.2% in the 1st quarter. Janus Henderson Group PLC now owns 851,839 shares of the company’s stock worth $12,113,000 after buying an additional 131,414 shares in the last quarter. Institutional investors own 47.91% of the company’s stock.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.